Recent Funding InMed Pharmaceuticals recently secured $6.96M in funding, indicating a potential investment in their rare cannabinoid therapeutics pipeline and creating opportunities for partnerships or collaborations.

Key Personnel Addition The addition of Dr. Barry Greenberg to InMed's Scientific Advisory Board highlights a strengthening of their R&D capabilities, presenting a chance to explore joint research projects or licensing agreements.

Innovative Therapies Development InMed's focus on developing therapies targeting Neurodegenerative diseases and dry age-related macular degeneration (AMD) opens doors for discussions on potential licensing deals or sales partnerships.

Strategic Conferences Participation Participation in events like the Emerging Growth Conference showcases InMed's commitment to innovation, presenting an opportunity for networking and potential collaborations with industry players.

Expertise in Alzheimer's Disease The recent appointment of Dr. David G. Morgan, a leading Alzheimer's expert, to InMed's Scientific Advisory Board positions the company as a key player in the Alzheimer's treatment space, offering opportunities for strategic alliances or joint ventures in this domain.